Sub-acute post-treatment dysphagia and shortness-of-breath symptom severity associates with survival and disease control in oropharyngeal cancer patients

Jarey H. Wang[1,2], Lance McCoy[1,3], Vivian Salama[1], Temitayo Ajayi[4], Cem Dede[1], Amy C. Moreno[1], Abdallah S.R. Mohamed[1], Katherine A. Hutcheson[1,5*], Clifton David Fuller[1], Lisanne V. van Dijk[1,6*], On behalf of MD Anderson Symptom Working Group

[1] Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

[2] Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas

[3] University of Houston, College of Medicine, Houston, TX, USA

[4] Department of Computational and Applied Mathematics, Rice University, Houston, TX, USA

[5] Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

[6] Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, NL

***Corresponding authors:**

Lisanne V. van Dijk, lvvan@mdanderson.org 713-825-5009
1515 Holcombe Blvd, FCT6.5000
Houston, TX 77030

Katherine A. Hutcheson, karnold@mdanderson.org
1515 Holcombe Blvd, FCT6.5000
Houston, TX 77030

Manuscript Word Count: 3010

Abstract

Importance: Post-treatment symptoms are a focal point of follow-up visits for head and neck cancer (HNC) patients. While symptoms such as dysphagia and shortness-of-breath early after treatment may motivate additional work up, their precise association with disease control and survival outcomes is not well established.

Objective: To investigate the associations between patient-reported swallowing, choking and shortness-of-breath symptoms at 3-to-6 months following radiotherapy and overall survival and disease control.

Design: Cohort study with prospectively collected symptom scores. Associations between the presence of moderate-to-severe swallowing, choking and mild-to-severe shortness-of-breath and treatment outcome were analyzed with Cox regression and Kaplan-Meier analyses.

Setting: Prospective symptom and outcome registry from single academic cancer referral center.

Participants: Consented sequential oropharyngeal cancer (OPC) patients with pathologically confirmed squamous cell carcinoma with known symptom scores at the 3–6-month follow-up after radiotherapy.

Main Outcome(s) and Measure(s): The main outcomes were overall survival (OS), and the secondary endpoints were local (LC), regional (RC), and distant disease control (DC). The potential predictors were post-treatment symptoms: patient-rated swallowing, choking and shortness-of-breath at 3-to-6 months after completion of radiotherapy.

Results: Symptom scores at 3-to-6 months were collected for 470 patients. The majority (91.3%) were HPV-positive. Median follow-up time was 31.7 months (IQR: 21.9-42.1). Univariable Cox regression showed significant associations between OS and all three symptoms of swallowing, choking, and shortness-of-breath ($p<0.0092$). Furthermore, a composite variable integrating scores of all three symptoms had the best predictive value for OS (c-index=0.75 [0.60-0.90]). Univariable analysis demonstrated that swallowing (HR=19.52 95%

CI: [3.57-106.79]) and choking (HR=11.19 [2.05-61.25]) symptoms were significantly associated with LC, no symptoms were associated with RC, and choking (HR=5.11 [1.71-15.25]) and shortness-of-breath (HR=3.94 [1.44-10.78]) were associated with DC. The same significant associated for OS were also seen for HPV-positive only subset analysis ($p<0.01$ for all symptoms).

Conclusions and Relevance: Quantitative early patient-reported measures of dysphagia and shortness-of-breath are significant predictors of OS and disease recurrence/progression in OPC patients. This was also observed for HPV-positive OPC only. Integrating quantitative post-treatment symptom surveys may guide individualized follow-up strategies to intensify or de-intensify tumor surveillance.

Introduction

Annually, more than 50,000 new cases of head and neck cancer (HNC) are diagnosed in the United States, resulting in an estimated 11,000 deaths[1]. With the decline in overall tobacco usage and the increase of prognostically-favorable human papilloma virus (HPV) related HNC tumors in recent decades, survival and cure rates have increased[2–5]. Better outcomes may also be attributed to improved treatment approaches[6], which typically involve a combination of surgery, radiation, and chemotherapy.

With improvement survival outcomes, new questions arise regarding optimal strategies for post-treatment evaluation and surveillance. Identification of early indicators (or predictors) of disease recurrence and overall survival is needed to personalize the follow-up of HNC patients more effectively. Use of such predictors could guide surveillance strategies, allowing clinicians to optimize HNC patient care by reducing redundant follow-up procedures (e.g. surveillance imaging) for low risk patients, while intensifying procedures for high risk patients to identify true recurrences early[7,8].

The majority of studies on HNC treatment outcome prediction have focused on pre-treatment variables, such as tumor information, imaging characteristics and comorbidities[9–14]. In contrast, the predictive value of post-treatment symptoms is less clear, despite the empiric use of patient reported symptoms as indicators of potential recurrence. In other words, even though patients with disease progression or recurrence are often symptomatic[11,15–17], few studies have provided quantitative survival risk assessment of specific symptoms. For instance, Boysen et al. found that 67% of the recurrences in their cohort were identified through symptom presentation[17], though the symptom types were not described or their severity quantified. Empirically, local head and neck recurrence can present with trouble swallowing or shortness-of-breath due to tissue infiltration or obstruction. To complicate things, these symptoms are also common treatment-induced toxicities following radiotherapy, and may indicate a general decline in swallowing muscle functionality (resulting in complications like nutritional deficits and

aspiration) rather than indicating tumor recurrence. With the assumption that severe dysphagia from treatment toxicity represents morbid functional issues like aspiration and cachexia, Shune et al. demonstrated that the prevalence of severe dysphagia (i.e. no oral intake status) at any time point was related to overall survival[18]. However, the study did not consider tumor recurrences in their analyses, making it difficult to evaluate the full relationship between dysphagia and survival. It is important to consider that early severe symptoms of dysphagia might be associated with vastly different clinical scenarios than late severe symptoms.

Our study investigates whether the patient-reported symptoms – swallowing, choking and shortness-of-breath – at 3-to-6 months after radiotherapy treatment are associated with overall survival (OS) and disease control (local, regional, or distant control) in patients diagnosed with primary oropharyngeal cancer (OPC). We further determine if a combination of symptoms signal unfavorable outcomes. Finally, the stratification value of these symptoms for OS and disease control was investigated for the subpopulation with HPV-positive disease.

Methods

Cohort selection and treatment

The patient symptom, tumor and clinical data were prospectively collected as part an active standardized follow-up registry study that was approved by The University of Texas MD Anderson Cancer Center (MDACC) Institutional Review Board (IRB) under [PA14-0947 data collection, PA11-0809 analysis]. This prospective registry enrolls patients evaluated at MDACC with a suspected or confirmed pathologic diagnosis of carcinoma of the oropharynx, including tonsil, base of tongue (BOT), or squamous cell carcinoma of the head and neck of unknown primary origin. For this study, sequential patients meeting these criteria that received radiotherapy with curative intent between 2015 and 2019 at MDACC were included. Generally, patients were treated with 70 Gy in 33 fractions, most commonly with intensity-modulated radiotherapy (IMRT), intensity-modulated proton therapy (IMPT), or volumetric modulated arc

therapy (VMAT). Patients that received previous radiation in the head and neck region (re-irradiated patients) were excluded. Additionally, only patients with known symptoms scores at the 3–6-month follow-up after treatment were included. The patient inclusion diagram is detailed in the **Supplemental Figure 1.**

MDASI symptom score collection

Symptom scores were systematically collected with the MD Anderson Symptom Inventory-Head and Neck Module (MDASI-HN) questionnaire, as part of the prospective observational cohort registry by the MD Anderson Oropharynx Program Patient Reported Outcomes/Function (PROF) Core[19]. This registry collects clinical, therapy and toxicity information systematically at baseline, weekly during and after radiotherapy (6 weeks, then 3-6, 12, 18 and 24 months). Symptoms in the MDASI-HN are rated on a scale from 0-10, where 0 indicates no subjective symptoms and 10 represents the worst symptom severity imaginable.

Symptom assessment

The symptoms investigated in this study are: patient-rated shortness-of-breath, choking/coughing (referred to as “choke”), and difficulty swallowing/chewing (referred to as “swallow”) at 3-6 months after completion of radiotherapy. Additionally, to assess the value of multiple symptoms together in predicting survival a composite variable of the three symptoms was created by adding the presence of the symptom together. Consequently, this composite variable represents the presence of 1, 2 or 3 of the symptoms. Symptom scores for “choke” and “swallow” were discretized as none-to-mild (MDASI score: 0-5) versus moderate-to-severe (MDASI score: 6-10). This cutoff for dysphagia was previously validated as being an important screening threshold for clinical and quality of life parameters[20]. Alternatively for shortness-of-breath, visual inspection of the OS Kaplan Meyer curves showed that the optimal discriminating threshold was 0-1 (none-to-barely) versus 2-10 (mild-to-severe). It may be that mild shortness-

of-breath symptoms are clinically significant for reasons that require additional exploration (as compared to mild dysphagia).

Outcome measures

The primary endpoint of this study was overall survival (OS), and the secondary endpoints were local, regional, and distant disease control. The time-to-event for OS and disease control was defined from start of definitive RT to time of death or first evidence of progression/recurrence as documented in follow-up visits, respectively. Residual tumor shortly after treatment that resolved over time was not considered as a progression or recurrence event.

Statistical analysis

Univariable Cox regression analysis was performed with the following parameters: age, HPV status, T stage, N stage, performance status, site of tumor (base of tongue, tonsil, unknown primary) and three symptoms (shortness-of-breath, choke, and swallow) and composite symptom score at the 3–6-month follow-up. Threshold for statistical significance was set at $p<0.05$. Performance of variables for predicting survival and disease control was assessed using the concordance index (c-index). Using the before mentioned thresholds, symptoms were evaluated as “low” or “high” in the Cox regression model for their association with overall survival and local, regional, and distant recurrence. All statistical analyses were performed using R statistical software (version 4.0.3).

Results

From an initial cohort of 617 patients, 470 (76%) could be included, since they had symptom scores reported at the 3–6-month follow-up after treatment. Demographics are shown in **Table 1**. Briefly, mean age at diagnosis was 61.7 ± 9.6 years. Consistent with the OPC population distribution, the majority of patients were male (89.4%), and most had tonsil (44.0%) or base of

tongue (48.1%) carcinomas. The vast majority of patient tumors were HPV-positive (91.3%). Only 12 patients died (2.6%), with a median time-to-event of 23.7 months (interquartile range: 16.8-29.1), and 35 patients had progression or recurrence (7.4%). These rates were noticeably less frequent than in previously reported HPV-positive cohorts in comparable time-frames[4]. Among the patients who died, 4 were related to early recurrence (<1 yr), 2 were related to late recurrence (≥1 yr), and 6 were unrelated to cancer. Median follow-up time for all patients was 31.7 months (interquartile range: 21.9-42.1) after end of radiotherapy.

Of the total 470 patients, 52 patients (11.1%) presented with moderate-to-severe *swallow* scores (score≥6); 26 patients (5.5%) with moderate-to-severe *choke* scores (score≥6); and 44 patients (9.4%) with mild-to-severe *shortness-of-breath* scores (score≥2). Based on these cutoffs, Kaplan-Meier (KM) curves showed a clear and significant difference in overall survival (OS) for these symptoms (**Figure 1**). When all three symptoms were considered in the composite variable, KM-analysis showed a significant reduction in OS for patients for whom all three symptoms were present (p<0.0001, log-rank test) (**Figure 1**). Univariable Cox regression analysis for OS (**Table 2**) showed significant associations between OS and 3–6-month MDASI symptom scores for shortness-of-breath (HR=6.26; 95% CI [1.88-20.85], p=0.0092), choke symptoms (HR=11.53 [3.47-38.31], p=0.001), and swallow symptoms (HR=10.12 [3.26-31.40], p=0.0003). Prediction performance for OS was highest for the swallow score (c-index=0.71 [0.57-0.86]). Moreover, the composite 3-symptom score outperformed all clinical and individual symptom variables (c-index=0.75 [0.60-0.90]). Only two clinical pre-treatment clinical variables were significantly associated with OS in this cohort: tumor subsite (p=0.0075) and N-stage (p=0.0209).

Kaplan-Meier analysis also showed significant associations between local control (LC) and swallow (p<0.0001), choke (p<0.0001), and shortness-of-breath scores (p=0.00061), as well as for the composite variable (p<0.0001) (**Figure 2A**). Depicted in **Table 2**, Cox regression analyses for LC was significant for swallow (HR=19.52 [3.57-106.79], p=0.0006) and choke

(HR=2.42 [2.05-61.25], p=0.021). Prediction performance of LC was highest for the swallow score (c-index=0.82 [0.64-1.00]). While shortness-of-breath was not independently significantly associated with LC (p=0.065), the composite 3-symptom score continued to outperform individual variables (c-index=0.84 [0.65-1.00]). While symptom scores were related to LC, they were not associated with regional control in KM or Cox regression analyses (**Figure 2B; Table 2**). Disease control for patients with moderate-severe dysphagia scores (swallow, choke) seemed to fall into two categories. For cases of local failure only, the mean latency between end of treatment and failure detection was 30.5 months (SD=12.6). For cases with simultaneously detected local failure and regional and/or distant spread, the mean latency was 9.1 months (SD=3.0).

For distant control (DC), KM-analysis showed significant DC differences for choke and shortness-of-breath scores (**Figure 2C**). Cox regression corroborated the association between DC and choke symptoms (HR=5.11 [1.71-15.25], p=0.014) and DC and shortness-of-breath (HR=3.94 [1.44-10.78], p=0.019) (**Table 2**). While having 3 symptoms in the composite variable was associated (p=0.00092) with decreased DC in KM-analysis (**Figure 2C,** bottom panel), performance on Cox regression (c-index=0.58 [0.47-0.69]) was equivalent to that of shortness-of-breath alone (**Table 2**). For cases of distant failure in patients with mild-severe shortness-of-breath scores, the mean latency to failure from end of treatment was 13.4 months (SD=6.9).

Mortality events that occur after treatment are frequently thought to be associated with disease progression or recurrence. Given the finding that swallow, choke, and shortness-of-breath symptoms were associated with OS and various measures of disease control, we queried whether deaths in the setting of progression or recurrence were associated with more severe symptoms (**Table 3**). Progression/recurrence related deaths were significantly associated with moderate-severe swallow (p=0.002) and choke (p=0.003) scores, but not associated with shortness-of-breath (p=0.101).

To ensure that these results were not simply reflective of the HPV-negative patients in our cohort, we repeated the analysis with just the 429 HPV-positive patients. Within the HPV-positive group, OS continued to stratify significantly based on symptom severity for swallow ($p=0.00014$), choke ($p=0.0097$), and shortness-of-breath ($p<0.0001$) in KM-analysis (**Supplemental Figure 2**). Analysis of local control (LC) also showed a significant association between LC and swallow scores ($p=0.0042$) as well as LC and choke scores ($p=0.044$) **(Supplemental Figure 3A)**. The association between LC and choke symptoms appeared to be driven by events that occurred late (>3 years) after treatment. In contrast to the full patient cohort, shortness-of-breath was not associated with LC in HPV-positive patients. Similar to the full cohort, KM-analysis showed a significant association between distant control (DC) and shortness-of-breath ($p=0.0097$) (**Supplemental Figure 3C**). However, there was no association between DC and choke symptoms.

Discussion

Along with improved therapeutic approaches, understanding baseline predictors of survival like HPV-status have helped establish HNC care. However, how individual patient factors at post-treatment follow-ups can be used to guide clinical care is less concretely defined and thus controversial. This study demonstrates that symptom presentation in the sub-acute setting after radiotherapy can guide current surveillance strategies that are geared toward early detection of treatment failure. We found significant associations between severity of patient-reported swallowing, choking and shortness-of-breath symptoms at 3-to-6 months after treatment and OS, as well as disease control. All three symptoms were significant predictors of OS (**Table 2**), with a combined variable of all three symptoms having the best predictive value (c-index=0.75). These findings are consistent with a finding from Nordgren et al., who reported that subjective swallow scores (based on the EORTC Quality of Life Questionnaire-Head and Neck module) at the 1-year follow-up were significantly different for patients that survived at 5 years compared to

those that died in the interim[11]. However, in addition to the different time for symptom reporting, it was unclear whether the observed association was related to recurrence or progression as opposed to treatment side effects[11].

Our results show that in addition to predicting OS, early symptoms of dysphagia (swallow and choke) are also significantly associated with local disease control, while symptoms of choke and shortness-of-breath are predictors of distant disease control. Specifically, of the 52 patients that experience moderate-to-severe swallowing symptoms (MDASI score≥6), 7.7% had local failure and 11.5% died compared to only 0.7% and 1.4% for both outcomes, respectively, in the patients with no-to-mild swallowing symptoms (**Table 3**). This is also reflected in the hazard ratios (**Table 2**), demonstrating that patient with moderate-to-severe swallowing symptoms are approximately 10 times as likely to die (95% CI: 3.3-31.4), and approximately 20 times more likely to have a local recurrence (95% CI: 3.6-107). Early symptoms of choking showed similar hazard ratios to swallowing for OS. Choking symptoms were also significantly associated with both local control (with a lower HR≈11) and distant metastasis (HR≈5), suggesting that different dysphagia symptoms associate with different outcomes. Shortness-of-breath seemed to be primarily an identifier for distant control (HR≈4, p=0.0194).

Previous retrospective studies have reported that most patients with disease recurrence had subjective symptoms at some time prior or during diagnosis of recurrence[11,15–17]. We now establish that already at 3-to-6 months after radiotherapy the presence of moderate-severe dysphagia and mild-severe shortness-of-breath can indicate mortality risk. Additional analyses showed no relation between higher scores of swallow, choke, and shortness-of-breath at the 6-week follow-up and OS (data not presented). This is likely because both treatment-induced symptoms have not resolved immediately post-treatment, combined with that the tumor is still partially present. At the 3-to-6-month period acute radiation damage may be resolved, and such severe symptoms then warrant greater concern for recurrence.

Our results also suggest that follow-up symptoms may only portend recurrence in some instances, whereas they may be associated with survival for alternative reasons in other instances. This partly agrees with findings by Shune et al. that mortality can also be caused by the symptoms directly[18]. They argue that a large fraction of HNC patients demonstrating severe dysphagia also exhibit malnutrition, weight loss, and impaired immune function, which often results in cachexia, fatigue, infection risk, or death[21,22]. In contrast to the hypothesis that more severe dysphagia leads to mortality through functional decline, our data suggest that death for patients with more severe dysphagia symptoms (**Table 3**) are more often cancer-related (swallowing: 66%, 4/6 deaths; choking: 75%, 3/4 deaths). However, symptoms like shortness-of-breath may have more diverse etiologies. Shortness-of-breath may indicate cancer-related pathologies like airway obstruction and pulmonary metastases or may be a more general indicator of decreased performance status. Of the four patients with high shortness-of-breath scores who died, two had pulmonary metastases and two had no evidence of recurrence (**Table 3**). In addition, while mild-severe shortness-of-breath was associated with worse overall survival, there was no association between mild-severe symptoms and deaths related to recurrence (**Table 3**, p=0.101).

Overall, it is notable that symptom severity – not simply symptom occurrence – is significantly associated with outcomes. This argues for the benefit of quantitative measures of patient reported symptoms during surveillance. Ideally, movement toward standardized, quantitative measures of post-treatment symptoms will help enable the development of more accurate predictive models that will guide surveillance strategies.

The primary limitation of this study is the low number of events, which is likely caused by the high number of patients with HPV-positive OPC (>90%), which has significantly better prognosis[23,24]. This complicates drawing definite conclusion from our study. More research is needed to verify our results in larger cohort, as well as test the results in a more HPV-negative dominant cohort, which is generally the case in European HNC populations. That being said, the

HPV prevalence is a correct reflection of the current OPC population treated at MDACC (as all treated OPC patients were included), which resembles the current incidence of HPV-related OPC in the United States. Importantly, analyses in the HPV-positive OPC cohort showed that our results were not simply reflective of identifying the HPV-negative OPC patients in our study. Notably, HPV status was not significant in univariable analyses, which would likely be different in a larger dataset with more HPV-negative OPCs. An additional limitation is the median follow-up time (31.7 months), which limits analysis of late-onset symptoms. A few studies with extended follow-up have noted the importance of late symptoms as potential indicators of tumor recurrence and toxicities[17,25]. For example, in one review 15% of HNC patients treated with chemoradiation developed very late dysphagia (>2.5 years from end of treatment) that was most associated with T-stage, secondary malignancy, and total tongue dose[25].

In conclusion, post-treatment follow-up and surveillance should be tailored to individual needs based on their clinical presentation and symptomology[7,8,16,17]. Our results demonstrate that patient that report moderate-to-severe swallowing, choking or mild-to-severe shortness-of-breath symptoms as early as 3-to-6 months after treatment have a significantly higher mortality and treatment failure risk. Therefore, more intensified tumor follow-up surveillance may be advised in patients with these symptoms, particularly if all three are present. These results were also applicable in the cohort with only HPV-positive OPC patients.

Acknowledgments

Conflicts of interest

The authors declare no conflicts of interest.

Funding statement

Direct infrastructure support is provided by the multidisciplinary Stiefel Oropharyngeal Research Fund of the University of Texas MD Anderson Cancer Center Charles and Daneen Stiefel Center for Head and Neck Cancer, and the NIH/NCI Grant (P30CA016672).

Dr. van Dijk, received/receives funding and salary support from the Dutch organization NWO ZonMw during the period of study execution via the Rubicon Individual career development grant.

Dr. Hutcheson, Mohamed, and Fuller received/receives funding and salary support unrelated to this project during the period of study execution from: the NIH National Cancer Institute (NCI) Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (R01CA218148).

Dr. Mohamed, and Fuller received/receives funding and salary support unrelated to this project during the period of study execution from: the National Institutes of Health (NIH) National Institute for Dental and Craniofacial Research (NIDCR) Establishing Outcome Measures Award (R01DE025248/R56DE025248).

Mr. McCoy is funded by NIH Research Supplements to Promote Diversity in Health-Related Research (R01DE025248-S02).

Dr. Fuller received funding unrelated to this project during the period of study execution from NIH/NCI Cancer Center (P30CA016672, P50 CA097007, and R01CA2148250); from NIH/NIBIB (R25EB025787-01); from NIH/NSF (NSF1557679); NSF-CMMI grant (NSF1933369); and the Sabin Family Foundation.

References

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. *CA. Cancer J. Clin.* **70**, 7–30 (2020).
2. Licitra, L. *et al.* High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. *J. Clin. Oncol.* **24**, 5630–5636 (2006).
3. Sedaghat, A. R. *et al.* Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. *Laryngoscope* **119**, 1542–1549 (2009).
4. Ang, K. K. *et al.* Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. *N. Engl. J. Med.* **363**, 24–35 (2010).
5. Mourad, M. *et al.* Epidemiological Trends of Head and Neck Cancer in the United States: A SEER Population Study. *J. Oral Maxillofac. Surg.* **75**, 2562–2572 (2017).
6. Lo Nigro, C., Denaro, N., Merlotti, A. & Merlano, M. Head and neck cancer: improving outcomes with a multidisciplinary approach. *Cancer Manag. Res.* **9**, 363–371 (2017).
7. Corpman, D. W. *et al.* Posttreatment surveillance PET/CT for HPV-associated oropharyngeal cancer. *Head Neck* hed.25425 (2018). doi:10.1002/hed.25425
8. Ho, A. S. *et al.* Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. *Cancer* **119**, 1349–1356 (2013).
9. Baptistella, A. *et al.* Weight loss as a prognostic factor for recurrence and survival in oropharyngeal squamous cell carcinoma patients. *Mol. Clin. Oncol.* (2018). doi:10.3892/mco.2018.1737
10. Lango, M. N. *et al.* Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. *Cancer* **120**, 840–847 (2014).
11. Nordgren, M. *et al.* Quality of life in oral carcinoma: A 5-year prospective study. *Head*

Neck **30**, 461–470 (2008).

12. Quinten, C. *et al.* Patient Self-Reports of Symptoms and Clinician Ratings as Predictors of Overall Cancer Survival. *JNCI J. Natl. Cancer Inst.* **103**, 1851–1858 (2011).
13. Reyes-Gibby, C. C. *et al.* Survival Patterns in Squamous Cell Carcinoma of the Head and Neck: Pain as an Independent Prognostic Factor for Survival. *J. Pain* **15**, 1015–1022 (2014).
14. Aerts, H. J. W. L. *et al.* Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. *Nat. Commun.* **5**, (2014).
15. Agrawal, A., DeSilva, B. W., Buckley, B. M. & Schuller, D. E. Role of the Physician Versus the Patient in the Detection of Recurrent Disease Following Treatment for Head and Neck Cancer. *Laryngoscope* **114**, 232–235 (2004).
16. Spector, M. E. *et al.* Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: Are we changing life expectancy? *Laryngoscope* **122**, 1507–1511 (2012).
17. Boysen, M. E., Zätterström, U. K. & Evensen, J. F. Self-reported symptoms to monitor recurrent head and neck cancer-analysis of 1,678 cases. *Anticancer Res.* **36**, 2849–2854 (2016).
18. Shune, S. E., Karnell, L. H., Karnell, M. P., Van Daele, D. J. & Funk, G. F. Association between severity of dysphagia and survival in patients with head and neck cancer. *Head Neck* **34**, 776–784 (2012).
19. Rosenthal, D. I. *et al.* Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module. *Head Neck* **29**, 923–931 (2007).
20. Grant, S. *et al.* Single-item discrimination of quality-of-life–altering dysphagia among 714 long-term oropharyngeal cancer survivors: Comparison of patient-reported outcome measures of swallowing. *Cancer* **125**, 1654–1664 (2019).

21. Stephens, N. A., Skipworth, R. J. E. & Fearon, K. C. H. Cachexia, survival and the acute phase response. *Curr. Opin. Support. Palliat. Care* **2**, 267–274 (2008).

22. Gorenc, M., Kozjek, N. R. & Strojan, P. Malnutrition and cachexia in patients with head and neck cancer treated with (chemo)radiotherapy. *Reports Pract. Oncol. Radiother.* **20**, 249–258 (2015).

23. Vigneswaran, N. & Williams, M. D. Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis. *Oral Maxillofac. Surg. Clin. North Am.* **26**, 123–141 (2014).

24. Li, H. *et al.* Association of Human Papillomavirus Status at Head and Neck Carcinoma Subsites With Overall Survival. *JAMA Otolaryngol. Neck Surg.* **144**, 519 (2018).

25. Gharzai, L. A. *et al.* Characterization of very late dysphagia after chemoradiation for oropharyngeal squamous cell carcinoma. *Oral Oncol.* **111**, 104853 (2020).

Tables:
Table 1: Patient, disease, and treatment characteristics.

	n	SD / %
Total	470	
Age (SD)	61.66	(9.61)
Sex (%)	420	(89%)
	50	(11%)
T stage (%)		
T1	145	(31%)
T2	169	(36%)
T3	67	(14%)
T4	57	(12%)
T0	32	(7%)
N stage (%)		
N0	42	(9%)
N1	127	(27%)
N2a	33	(7%)
N2b	193	(41%)
N2c	67	(14%)
N3	8	(2%)
p16/HPV status (%)		
Negative	31	(7%)
Positive	429	(91%)
Unknown	10	(2%)
Performance score (%)		
Unknown	18	(4%)
0	329	(70%)
1	117	(25%)
2	5	(1%)
3	1	(0%)
Tumor site (%)		
Tonsil	207	(44%)
Base of tongue	226	(48%)
Pharyngeal wall	4	(1%)
Multiple sites	5	(1%)
Unknown primary	28	(6%)
Treatment (%)		
Concurrent chemoRT	329	(70%)
Induction + concurrent chemoRT	66	(14%)
RT alone	75	(16%)

Table 2: Cox regression analysis of survival and disease control based on patient and tumor characteristics as well as 3-to-6 month reported symptoms post-treatment.

OS	β	HR (95% CI)	p-value	c-index	n
M6 sob choke swallow*	1.18	3.24 (2.02-5.22)	**0.0000**	0.75	470
M6 swallow	2.31	10.12 (3.26-31.40)	**0.0003**	0.71	470
M6 choke	2.44	11.53 (3.47-38.31)	**0.0010**	0.65	470
site of tumor	1.23	3.42 (1.39-8.41)	**0.0075**	0.71	470
M6 sob	1.83	6.26 (1.88-20.85)	**0.0092**	0.63	470
N stage	0.65	1.92 (1.07-3.44)	**0.0209**	0.67	470
T stage	0.61	1.83 (0.82-4.12)	0.1385	0.62	470
HPV status	-1.04	0.35 (0.08-1.63)	0.2341	0.55	460
performance	0.53	1.70 (0.63-4.57)	0.3217	0.54	452
sex	0.33	1.39 (0.18-10.79)	0.7402	0.51	470

LC	β	HR (95% CI)	p-value	c-index	n
M6 swallow	2.97	19.52 (3.57-106.79)	**0.0006**	0.82	470
M6 sob choke swallow*	1.32	3.74 (1.91-7.34)	**0.0009**	0.84	470
M6 choke	2.42	11.19 (2.05-61.25)	**0.0212**	0.61	470
N stage	0.77	2.16 (0.95-4.94)	**0.0499**	0.70	470
M6 sob	1.85	6.34 (1.15-34.96)	0.0645	0.66	470
site of tumor	1.07	2.91 (0.80-10.51)	0.1063	0.70	470
performance	0.93	2.53 (0.69-9.23)	0.2058	0.65	452
T stage	0.63	1.88 (0.59-5.98)	0.2824	0.62	470
HPV status	-1.27	0.28 (0.03-2.53)	0.3221	0.59	460
sex	-0.44	0.65 (0.08-5.55)	0.7045	0.54	470

RC	β	HR (95% CI)	p-value	c-index	n
T stage	0.59	1.80 (0.96-3.38)	0.0662	0.61	470
sex	-1.05	0.35 (0.13-0.97)	0.0665	0.60	470
M6 sob choke swallow*	0.46	1.59 (0.93-2.71)	0.1267	0.57	470
HPV status	-1.08	0.34 (0.10-1.18)	0.1318	0.57	460
M6 swallow	0.82	2.26 (0.75-6.79)	0.1814	0.57	470
N stage	0.26	1.30 (0.88-1.94)	0.1874	0.57	470
site of tumor	0.40	1.50 (0.73-3.07)	0.2742	0.56	470
M6 sob	0.74	2.10 (0.61-7.18)	0.2785	0.55	470
M6 choke	0.81	2.26 (0.52-9.75)	0.3274	0.51	470
performance	0.32	1.38 (0.60-3.20)	0.4667	0.54	452

DC	β	HR (95% CI)	p-value	c-index	n
M6 sob choke swallow*	0.71	2.04 (1.30-3.19)	**0.0077**	0.58	469
M6 choke	1.63	5.11 (1.71-15.25)	**0.0139**	0.56	469
M6 sob	1.37	3.94 (1.44-10.78)	**0.0194**	0.58	469
N stage	0.32	1.37 (0.92-2.05)	0.1138	0.58	469
M6 swallow	0.81	2.24 (0.75-6.67)	0.1831	0.54	469
HPV status	-0.86	0.42 (0.12-1.44)	0.2137	0.55	459
performance	0.49	1.63 (0.77-3.44)	0.2258	0.53	451
T stage	0.29	1.34 (0.73-2.46)	0.3540	0.56	469
site of tumor	-0.09	0.91 (0.44-1.90)	0.8089	0.51	469
sex	0.13	1.14 (0.26-4.90)	0.8619	0.51	469

*****MDASI combined predictor is a multivariable model based on scores of three symptoms: swallow, choke, and shortness of breath.

Abbreviations: M6: 3-to-6-month MD Anderson Symptom Inventory-Head and Neck Module; sob, shortness of breath

Table 3: Outcomes for patients with high versus low scores for MDASI for swallow, choke, shortness of breath.

		Totals (% of total)	Local failure	Regional failure	Distant failure	Deaths	Deaths related to progression or recurrence
Swallowing	High	52	4 (7.7%)	4 (7.7%)	4 (7.7%)	6 (11.5%)	4 (7.7%)
	Low	418	3 (0.7%)	15 (3.6%)	17 (4.1%)	6 (1.4%)	2 (0.5%)
	p-value		**0.005**	0.147	0.273	**0.001**	**0.002**
Choke	High	26	2 (7.7%)	2 (7.7%)	4 (15.4%)	4 (15.4%)	3 (11.5%)
	Low	444	5 (1.1%)	17 (3.8%)	17 (3.8%)	8 (1.8%)	3 (0.7%)
	p-value		0.052	0.283	**0.023**	**0.003**	**0.003**
Shortness of breath	High	44	2 (4.5%)	3 (6.8%)	5 (11.4%)	4 (9.1%)	2 (4.5%)
	Low	426	5 (1.2%)	16 (3.8%)	16 (3.8%)	8 (1.9%)	4 (0.9%)
	p-value		0.133	0.407	**0.037**	**0.019**	0.101
Composite variable	High	8	1 (12.5%)	1 (12.5%)	2 (25%)	3 (37.5%)	2 (25%)
	Low	462	6 (1.3%)	18 (3.9%)	19 (4.1%)	9 (1.9%)	4 (0.9%)
	p-value		0.126	0.302	0.064	**0.002**	**0.006**

*Thresholds for “high” versus “low” score categories stated: “high” for swallow is a score≥6; for choke, a score≥6; and for shortness of breath, a score≥2. For the composite variable “high” is denoted as having “high” scores for all three symptoms, versus “low” denoting “high” scores for two or fewer symptoms. P-values obtained using Fisher’s exact test.

Figures:

Figure 1: Kaplan-Meier analysis of overall survival based on patient reported metrics at the 3-to-6 month follow-up.



Figure 2: Kaplan-Meier analysis of local, regional, and distant disease control based on patient reported metrics at the 3-to-6 month follow-up.



Supplemental Figure 1: Inclusion and exclusion criteria for patient selection.



Supplemental Figure 2: Kaplan-Meier analysis of overall survival for p16/HPV positive patients based on patient reported metrics at the 3-to-6 month follow-up.



Supplemental Figure 3: Kaplan-Meier analysis of local, regional, and distant disease control for p16/HPV positive patients based on patient reported metrics at the 3-to-6 month follow-up.